BioSpace News Archive

− Dr. Shacham Recognized for Her Contributions to Science and Inspiring Others with Her Vision, Leadership and Achievement

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth enabled, virtualized outpatient healthcare treatment company, today announced that it has priced its previously announced underwritten public offering of 1,700,000 shares of its 9.50% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock“) at $25.00 per share,

6-month contract anticipates demand of 3,000 tests per day Todos has the right to supply up to 30,000 tests per day if demand increases for the lab NEW YORK, NY, REHOVOT, Israel, and SINGAPORE, Aug. 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease,

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”), convened on Thursday, August 20, 2020, has been adjourned and will resume on September 3, 2020 at 10:00 a.m. Pacific Time, to permit additional time for solicitation of proxies with respect to two of the proposals described in the company’s notice of meeting and definitive proxy statement filed with the Securities and

European Commission Approves KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older – For the first time, up to 10,000 people in Europe ages 12 years and older with one F508del mutation and one minimal function mutation will be eligible for a medicine that treats the underlying cause of cystic fibrosis – – People 12 years of age and older who have two F508del mutations will

Coherus BioSciences, Inc., announced that effective August 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,000 shares of the common stock of the Company to seven newly hired non-officer employees, with a per share exercise price of $19.85, the closing trading price on the grant date.

- HBM’s Bispecific Antibody BCMA X CD3 (HBM7020) has a unique 2+1 format built by the proprietary fully human heavy chain only antibody derived from Harbour HCAb Mice® - HBM7020 shows potent tumor killing efficacy with limited cytokine release preclinically which suggests its significant therapeutic window [21-August-2020] CAMBRIDGE, Mass. , ROTTERDAM , Nethe

PDC Wellness and Personal Care Co. and its subsidiaries (“PDC” or the “Company”), a leading growth-oriented wellness and personal care company, announced today that Pete Columbia, the Company’s President, has been promoted to Chief Executive Officer and a member of the Company’s Board of Directors effective September 1, 2020. Mr. Columbia will continue to lead the Company’s operational and commercial organizations.

Phase 1b clinical trial will evaluate the safety and pharmacological activity of SAB-185 in COVID-19 patients Second study initiated this month testing SAB-185 for the treatment of COVID-19 SIOUX FALLS, S.D.--( BUSINESS WIRE )-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, today announced the dosing of the first patient in its Phase 1b

Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2020 on Thursday, 27 August 2020 . A presentation by the Nordic Nanovector’s senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, Meeting Room: